Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2008-05-20
2008-05-20
Nguyen, Bao-Thuy L. (Department: 1641)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C435S344100, C435S007200, C435S007230, C435S330000, C436S512000, C436S541000, C436S548000, C436S057000, C436S064000, C530S413000, C530S228000
Reexamination Certificate
active
10022631
ABSTRACT:
The present invention relates to the field of site directed therapy. More specifically the invention relates to site directed radio therapy, and provides a method for production of radioconjugates and an apparatus for radioimmunotherapy. The method, conjugates and apparatus can be practicalized without the need for radioactive shielding and/or airtight facilities. Without these restrictions the invention provides a simple and efficient means of therapy at the bed-side of the patient.
REFERENCES:
patent: 4001387 (1977-01-01), Barak et al.
patent: 4296785 (1981-10-01), Vitello
patent: 4305922 (1981-12-01), Rhodes
patent: 4454106 (1984-06-01), Gansow et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4663129 (1987-05-01), Atcher
patent: 4732864 (1988-03-01), Tolman et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4828991 (1989-05-01), Hanna et al.
patent: 4833329 (1989-05-01), Quint et al.
patent: 4894364 (1990-01-01), Greer
patent: 4923985 (1990-05-01), Gansow et al.
patent: 5038046 (1991-08-01), Norman et al.
patent: 5246691 (1993-09-01), Geerlings et al.
patent: 5254328 (1993-10-01), Herscheid et al.
patent: 5292868 (1994-03-01), Subramanian
patent: 5296216 (1994-03-01), Turner
patent: 5355394 (1994-10-01), Van Greel
patent: 5428154 (1995-06-01), Gansow et al.
patent: 5443816 (1995-08-01), Zamora et al.
patent: 5641471 (1997-06-01), Geerlings
patent: 0306168 (1988-08-01), None
patent: WO 90/15625 (1990-12-01), None
Macklis et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science (1988), vol. 240, No. 4855, pp. 1024-1026.
Rotmensch et al. Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy. Gynecologic Oncology (1990), vol. 38, No. 3, pp. 478-485. <abstract only>.
D.S. Wilbur, “Potential Use of a α-emitting Radionucleotides in the Treatment of Cancer”,Antibody, Immunoconjugates and Radiopharmaceuticals, 4(1): 85-97 (1991).
T. Mitsugashira et al., “Preparation of Traces for Actinium, Thorium, Proactinium and Uranium”,SPEY, Min. Educ. Sci. & Cult., Tokyo, 9: 111-116 (1984).
S. Suzuki, “Solution Chemistry of Light Actinude Elements”, Japan—US Seminar on Torium fuel reactors—Proceedings, Nara, Japan, Oct. 18-22, 1982 (Tokyo, 1985), pp. 137-143.
S. Mirzadeh et al., “Radiometal Labeling of Immunoproteins: Covalent Linkage of 2-(-4Isothiocyanatobenzyl)di-ethylenetriaminepentaacetic Acid Ligends to Immunoglobulin”,Bioconjugate Chem., 1: 59-65 (1990).
Zwierzina et al.,Stem Cells, 11: 144 (1993).
Kozak et al.,Tibtech, 4(10): 259 (1986).
Goldenberg,Arch. Pathol. Lab Med., 112: 580 (1988).
M. Chatterjee et al.,Cancer Immunol. Immunopathol., 38: 75-82 (1994).
Osband,Immunol. Today.11(6): 193-195 (1990).
Curti,Crit. Rev. Oncol. Hematol., 14: 29-39 (1993).
Jain,Scientific American271: (1): 58-65 (1994).
D.R. Fischer, “Alpha-Particle Emitters in Medicine”, Proceedings of a symposium held at Loews L'Enfant Plaza Hotel, Washington, DC, Sep. 21 and 22, 1989, pp. 194-214.
M.R. McDevitt et al., “Alpha Particle Emitting Bismuth-213 Cyclohexylbenzyl DTPA Constructs of Monoclonal Antibodies for Therapy of Cancer”,Cancer Res., 1998.
M. Brechbiel and O.A. Gansow, Synthesis of C-Functionalizedtrans-Cyclohexyldiethylenetriaminepenta-acetic Acids for Labelling of Monoclonal Antibodies with the Bismuth-212 α-Particle Emitter,J. Chem. Soc. Perkin Trans., pp. 1173-1178 (1992).
Scheinberg et al., “Targeting in Erythroleukemic Mice . . . ”, Monoclonal Antibodies Drug. Dev., Process Jacob Abel Symp. for Drug Dev., pp. 159-171 (1982).
“Astatine-211: It's Possible Applications in Cancer Therapy”, Brown,International Journal of Radiation Applications and Instrumentation, Part A, vol. 37, No. 8, pp. 789-798 (1986).
“Preparation of224RA for Therapy of Ankylosing Spondylitis”, Delikan Health, Physics, vol. 35, No. 1, pp. 21-24 (1978).
Lambrecht, “Radionuclide Generators”, Radiochimica Acts 34, 9-24 (1983), R. Oldenbourg Verlag, Munich, p. 19.
Spitsyn & Mikheev, “Generators for the Production of Short-Lived Radioisotopes, ” Atomic Energy Review, 9(4): 787 et seq. (1971), International Atomic Energy Commission, Vienna, pp. 820-823.
Riechmann et al., “Reshaping human antibodies for therapy”, Nature, 332:323-327 (1988), Macmillan Magazines, London.
DeNardo et al., “Fractionated Radioimmunotherapy of 8-Cell Malignancies with131l-Lym-1”, Cancer Res. (Suppl), 50: 1014s-1016s (1990).
Actinium Pharmaceuticals, Inc.
Nguyen Bao-Thuy L.
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Method and means for site directed therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and means for site directed therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and means for site directed therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3928875